Johnson & Johnson (NYSE:JNJ) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Johnson & Johnson (NYSE:JNJ) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $215.00 price objective on the stock.

Several other analysts have also recently issued reports on JNJ. Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a buy rating to a strong-buy rating in a research note on Friday, August 16th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an equal weight rating in a research report on Thursday, July 18th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an outperform rating to a neutral rating and cut their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, TD Cowen decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a buy rating for the company in a research report on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $173.21.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $164.41 on Tuesday. The company has a market cap of $395.68 billion, a P/E ratio of 10.25, a P/E/G ratio of 2.73 and a beta of 0.52. The business’s 50 day moving average price is $157.57 and its 200-day moving average price is $153.83. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $27,000. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the first quarter worth about $31,000. MFA Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $46,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.